A guinea pig model for cough variant asthma and role of tachykinins.
Cough variant asthma is known as a major cause of chronic cough. Fundamental features of cough variant asthma are prolonged nonproductive cough responding to bronchodilator therapy, no history of wheezing or dyspnea attack, normal cough sensitivity, and slightly increased bronchial responsiveness. Animal model of cough variant asthma has not been reported. The aim of this study was to establish an animal model for studying detailed pathophysiology of cough variant asthma. Bronchial responsiveness to methacholine and cough reflex sensitivity to capsaicin were measured 72 hours after antigen (ovalbumin, OA) inhalation in actively sensitized guinea pigs. Next, cough number and specific airway resistance (sRaw) were measured during 20 minutes following reinhalation of OA solution, which was carried out 72 hours after the first OA inhalation, and then total cell number and cell differentials in bronchoalveolar lavage fluid (BALE) were measured. Bronchial responsiveness to methacholine, but not cough reflex sensitivity to capsaicin, was significantly increased 72 hours after the first inhalation of OA solution. Number of coughs, sRaw and total cell number in BALF increased significantly by the OA reinhalation, and the cough number and the increase in sRaw were significantly suppressed by beta2 agonist, procaterol. FK224, a specific neurokinin (NK) receptor antagonist, did not significantly influence the OA reinhalation-induced cough and increase in sRaw and total cell number in BALF in this model In conclusion, pathophysiologic feature of this animal model is similar to that of clinical cough variant asthma. Tachykinins may not play an important part in antigen-induced cough associated with bronchoconstriction and airway inflammation in cough variant asthma.
Nishitsuji
Masaru
M
Respiratory Medicine, Cellular Transplantation Biology, Kanazawa Graduate University School of Medicine, Kanazawa, Japan. masaruun@m8.dion.ne.jp
Fujimura
Masaki
M
Oribe
Yoshitaka
Y
Nakao
Shinji
S
D000403:Airway Resistance / Q000187:drug effects; D000485:Allergens / Q000276:immunology; D000818:Animals; D001249:Asthma / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D001985:Bronchial Provocation Tests; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000627:therapeutic use; D002211:Capsaicin / Q000008:administration & dosage / Q000494:pharmacology; D003371:Cough / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology*; D004195:Disease Models, Animal; D006168:Guinea Pigs; D008297:Male; D016210:Methacholine Chloride / Q000008:administration & dosage / Q000494:pharmacology; D010047:Ovalbumin / Q000276:immunology; D010456:Peptides, Cyclic / Q000627:therapeutic use; D017265:Procaterol / Q000627:therapeutic use; D015320:Tachykinins / Q000502:physiology*
D000485:Allergens; D001993:Bronchodilator Agents; D010456:Peptides, Cyclic; D015320:Tachykinins; D016210:Methacholine Chloride; C075570:FK 224; D010047:Ovalbumin; D002211:Capsaicin; D017265:Procaterol